Boundless Bio, Inc. Common Stock (BOLD NASDAQ) stock market data APIs
$1.786
0.08(4.7%)
as of March 24, 2025
Boundless Bio, Inc. Common Stock Financial Data Overview
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Prev. Close
1.7095
Open
1.786
High
1.786
Low
1.6275
52 wk Range
1.55-15.24
Market Cap
38 356 K
Shares Outstanding
22 300 K
EPS
-0.74
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Boundless Bio, Inc. Common Stock data using free add-ons & libraries
Get Boundless Bio, Inc. Common Stock Fundamental Data
Boundless Bio, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -67 748 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-08
- EPS/Forecast: -0.7433
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Boundless Bio, Inc. Common Stock News
New
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...
Insiders are Amassing These 10 Stocks in April
In this article, we will take a detailed look at Insiders are Amassing These 10 Stocks in April. For a quick overview of such stocks, read our article Insiders are Amassing These 5 Stocks in April. ...
5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science
SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatmen...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – BOLD, INST, THOR
NEW YORK, Dec. 21, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Audentes Therapeutics, Inc. (NASDAQ: BOLD) The in...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
